THE 2026 ELITE
PHARMACOLOGY MASTER
GUIDE: LILLEY’S CANADIAN
EDITION
Includes Detailed Visuals, 55+ Modular Questions, & Expert Distractor Analysis 2026/2027 Edition
LEGAL DISCLAIMER
The content presented in The 2026 Elite Pharmacology Master Guide is an independent
educational resource developed for the purpose of exam preparation and clinical competency
enhancement. This document is not affiliated with, endorsed by, or connected to the National
Council of State Boards of Nursing (NCSBN), the College of Nurses of Ontario (CNO), the
Canadian Council for Practical Nurse Regulators (CCPNR), Elsevier, or any other official
regulatory or testing body.
All clinical scenarios, practice questions, and rationales are original works created by elite
instructional designers to mirror the cognitive complexity of the 2026/2027 licensure
examinations (NCLEX-RN, NCLEX-PN, CPNRE). While every effort has been made to ensure
accuracy in accordance with the 4th Edition of Lilley’s Pharmacology for Canadian Health Care
Practice and current Health Canada guidelines (2025-2026), medical knowledge is dynamic.
Users are advised to verify dosing, protocols, and legal scopes of practice with current
,institutionalsdandsdprovincialsddirectives.sdThissdguidesdissdasdcommercialsdassetsddesign
edsdtosdbridgesdthesdgapsdbetweensdacademicsdtheorysdandsdhigh-
stakessdclinicalsdjudgment;sditsddoessdnotsdconstitutesdlegalsdorsdmedicalsdadvice.
INTERACTIVEsdTABLEsdOFsdCONTENTS
**
● SectionsdI:sdThesdHigh-YieldsdToolkit
● ModulesdA:sdFundamentalssdofsdCanadiansdNursingsdPracticesd&sdLeg
alsdFrameworkssd(Q1–Q8)
● ModulesdB:sdAutonomicsd&sdCentralsdNervoussdSystemsdAgentssd(Q9–Q18)
● ModulesdC:sdCardiovascularsd&sdRenalsdPharmacologysd(Q19–Q30)
● ModulesdD:sdEndocrinesd&sdMetabolicsdTherapeuticssd(Q31–Q40)
● ModulesdE:sdRespiratory,sdAnti-Infective,sd&sdImmunesdModulationsd(Q41–Q48)
● ModulesdF:sdSpecialsdPopulations:sdGeriatrics,sdPediatrics,sd&sdDeprescribingsd(Q
49–Q55)
THEsd"HIGH-YIELDsdTOOLKIT"
MechanisticsdClarifier:sdDeconstru
ctingsdthesd"FatalsdPairs"
Insdthesdcontextsdofsdthesd2026sdexamsdcycle,sdrotesdmemorizationsdofsddrugsdclassessd
issdinsufficient.sdThesdNextsdGenerationsdNCLEXsd(NGN)sdandsdupdatedsdCPNREsdbluep
rintssdtestsdthesdcandidate'ssdabilitysdtosddistinguishsdbetweensdphysiologicallysdsimilarsdb
utsdclinicallysddistinctsdstates.sdThesdfollowingsdcomparisonsdtablesddissectssdthesdmostsdf
requentlysdconfusedsdconceptssdthatsdleadsdtosdcriticalsdsafetysderrors,sdintegratingsdspeci
ficsdCanadiansdnuancessdfromsdthesd2025–2026sdpracticesdstandards.
ConceptsdPair MechanisticsdDiverge ClinicalsdDifferentiat 2026sdCanadian
nce orsd(Thesd"Tell") sdPracticesdCo
ntext
,CholinergicsdCrisissd Cholinergic:sdExces Secretionssd&sdTimi TrapsdAlert:sdWhiles
vs. sivesdaccumulationsd ng:sdCholinergicsdCri dthesdTensilonsdtests
MyasthenicsdCrisis ofsdacetylcholinesd(A sis:sd"Wet"sdsympto dissdasdclassicsdexa
Ch)sdatsdthesdneuro mssd(Salivation,sdLac msdtopic,sd2026sdprot
muscularsdjunctionsd rimation,sdUrination,s ocolssdemphasizesdre
duesdtosdoverdosesd dDefecationsd- spiratorysdfailuresd
ofsdanticholinesterase sdSLUDge).sdOccurss managementsdfirst.sdI
sdtherapy.sdResultss d30-60sdminssdpost- ntubationsdtakessdpre
dinsdcontinuoussddep medication. cedencesdoversddiagn
olarizationsdandsdrec MyasthenicsdCrisis:sd osticsdtestingsdinsdac
eptorsddesensitization "Dry"sdweakness.sdR utesddistress.sdThesd
. espiratorysdfailuresdwi FDAsdandsdHealthsd
Myasthenic: thoutsdthesdexcessive Canadasdhavesdmove
sdsecretions.sdOccurs dsdawaysdfromsdEdro
sddue phoniumsdduesdto
tosdmissedsddosessdo
r
ConceptsdPair Mechanistic ClinicalsdDifferentiato 2026sdCanadian
Divergence r PracticesdContext
(Thesd"Tell")
InsufficientsdAChsdats infection.sdEdrophoni cardiacsdarrestsdrisk;sd
dthesdjunctionsdduesd umsd(Tensilon)sdTes looksdforsd"IcesdPack
tosddiseasesdexacerb tsdResponse:sdCholi sdTest"sdassdthesdmo
ationsd(autoimmunesd nergicsdCrisis:sdSymp dernsdbedsidesdaltern
destructionsdofsdrece tomssdWORSEN.sdMy ative.
ptors)sdor asthenicsdCrisis:sdSy
under-dosing. mptomssdIMPROVE.
SerotoninsdSyndro SS: NeuromuscularsdTon Withsdthesdrisesdofsd
mesd(SS)sdvs.sdNe Hypersensitivity/Oversti e:sdSS:sdHyperreflex polypharmacysdinsdC
urolepticsdMalignan sdmulationsdofsd5- ia,sdclonussd(rhythmic anadiansdmentalsdhealt
tsdSyndromesd(NM HT2Asdreceptorssdins sdjerking),sdandsdmy hsd(e.g.,sdcombiningsd
S) dthesdbrainstemsdand driasissd(dilatedsdpupi SSRIssdwithsdnewersd
sdspinalsdcord.sdOnse ls).sdNMS:sd"Lead- antipsychoticssdlikesdL
tsdissdRAPIDsd(hours pipe"sdrigidity,sdhyp urasidone),sddistinguis
).sdNMS:sdDopamines oreflexia,sdandsdnorm hingsdthesesdemergen
dD2sdreceptorsdblocka alsdpupils. tsdstatessdissdasdcritic
desdinsdthesdnigrostri Mnemonic:sd"SSsd=s alsdsafetysdcompetenc
atalsdpathwaysdandsd dShakingsd&sdsweaty y.sdThesdtreatmentsdf
hypothalamus. sd(fast);sdNMSsd=sd orsdSSsdissdCyprohep
OnsetsdissdGRADUAL Nosdmotionsd&sdslow tadine;sdforsdNMS,sdit
(dayssdtosdweeks). ." sdissdDantrolene.
, ACEsdInhibitorssd(- ACEsdInhibitors:sdBl ThesdCoughsd&sdAn RenalsdProtection:s
prils) ocksdthesdconversions gioedema:sdAccumula dBothsdaresdfirst-
vs.sdARBssd(- dofsdAngiotensinsdIsdt tionsdofsdBradykininsdi linesdforsddiabeticsd
sartans) osdIIsdandsdinhibitsdth nsdthesdlungssdcause nephropathysdinsdC
esdbreakdownsdofsdBr ssdthesddrysdcoughsd anada.sdThesd2026s
adykinin.sdARBs:sdBl andsdhighersdrisksdofs dguidelinessdemphasi
ocksdAngiotensinsdIIsd dangioedemasdinsdAC zesdswitchingsdtosdA
receptorssddirectly.sdD Esdinhibitors.sdARBssd RBssdimmediatelysdif
osdNOTsdaffectsdBrad aresdthesdalternativesd sdcoughsdimpactssda
ykininsdbreakdown. whensdthesesdsidesde dherence,sdassdadher
ffectssdoccur. encesdissdasdkeysdm
etricsdinsdchronic
diseasesdmanagement.
Heparinsd(Unfracti Heparin:sdActivatess MonitoringsdLabs:sd High-
onated)sdvs.sdWarf dAntithrombinsdIII,sdw Heparin:sdaPTTsd(Targ AlertsdStatus:sdISM
arin hichsdinactivatessdTh et:sd1.5– PsdCanadasd(2025)s
rombinsdandsdFactor 2.5xsdcontrol). dlistssdbothsdassdhigh
sdXa.sdWorkssdIMME Antidote:sdProtamines -
DIATELYsdinsdthesd dSulfate.sdWarfarin:sdI alert.sdUnderstanding
blood.sdWarfarin:sdI NRsd(Target:sd2.0– sdthesd"Bridge"sdissd
nhibitssdVitamin 3.0). vitalsdforsdtransitions
K- Antidote:sdVitaminsdK dofsdcaresd(hospitals
dependentsdsynthesis sd/sdPCC.sdBridgesdT dtosdcommunity).sdEr
sdofsdFactorssdII,sdVI herapy:sdBothsdaresd rorssdheresdaresdasd
I,sdIX,sdXsdinsdthesdl usedsdsimultaneously leadingsdcausesdofsd
iver.sdTakessdDAYSs sduntilsdINRsdissdthe readmission.sdBesda
dtosdworksd(Effect rapeutic. waresdofsdHITsd(Hep
dependssdonsddepletin arinsdInduced
g
ConceptsdPair Mechanistic ClinicalsdDifferentiato 2026sdCanadian
Divergence r PracticesdContext
(Thesd"Tell")
existingsdfactors). Thrombocytopenia)sdw
hichsdprohibitssdfutures
dHeparin/LMWHsduse.
Typesd1sd(DKA)sdvs.s DKA:sdAbsolutesdinsu Acidosissdvs.sdOsm 2026sdDiabetessdCan
dTypesd2sd(HHS)sdC linsddeficiencysdleadin olarity:sdDKA:sdKuss adasdUpdate:sdFluids
risis gsdtosdketosis.sdpHsd maulsdrespirationssd(b dresuscitationsdissdthe
<sd7.35,sdKetonessdin lowingsdoffsdCO2),sdfr sdprioritysdinsdboth.
sdurine/blood.sdRapids uitysdbreath,sdmetabol However,sdinsdDKA,s
donset.sdHHS:sdRelati icsdacidosis.sdHHS:sd dpotassiumsdreplacem
vesdinsulinsddeficiency Profoundsddehydration entsdmustsdoccursdbe
sdpreventssdketosissd ,sdconfusion/coma,sdN foresdinsulinsdifsdK+s
butsdallowssdseveresd Osdketones/acidosis. d<sd3.3sdmmol/Lsdtos
hyperglycemiasd(>34s dpreventsdcardiacsdar
dmmol/L)sdandsddehy rest.sdThissdsequenci
dration.sdGradual ngsdissda
onset. high-
PHARMACOLOGY MASTER
GUIDE: LILLEY’S CANADIAN
EDITION
Includes Detailed Visuals, 55+ Modular Questions, & Expert Distractor Analysis 2026/2027 Edition
LEGAL DISCLAIMER
The content presented in The 2026 Elite Pharmacology Master Guide is an independent
educational resource developed for the purpose of exam preparation and clinical competency
enhancement. This document is not affiliated with, endorsed by, or connected to the National
Council of State Boards of Nursing (NCSBN), the College of Nurses of Ontario (CNO), the
Canadian Council for Practical Nurse Regulators (CCPNR), Elsevier, or any other official
regulatory or testing body.
All clinical scenarios, practice questions, and rationales are original works created by elite
instructional designers to mirror the cognitive complexity of the 2026/2027 licensure
examinations (NCLEX-RN, NCLEX-PN, CPNRE). While every effort has been made to ensure
accuracy in accordance with the 4th Edition of Lilley’s Pharmacology for Canadian Health Care
Practice and current Health Canada guidelines (2025-2026), medical knowledge is dynamic.
Users are advised to verify dosing, protocols, and legal scopes of practice with current
,institutionalsdandsdprovincialsddirectives.sdThissdguidesdissdasdcommercialsdassetsddesign
edsdtosdbridgesdthesdgapsdbetweensdacademicsdtheorysdandsdhigh-
stakessdclinicalsdjudgment;sditsddoessdnotsdconstitutesdlegalsdorsdmedicalsdadvice.
INTERACTIVEsdTABLEsdOFsdCONTENTS
**
● SectionsdI:sdThesdHigh-YieldsdToolkit
● ModulesdA:sdFundamentalssdofsdCanadiansdNursingsdPracticesd&sdLeg
alsdFrameworkssd(Q1–Q8)
● ModulesdB:sdAutonomicsd&sdCentralsdNervoussdSystemsdAgentssd(Q9–Q18)
● ModulesdC:sdCardiovascularsd&sdRenalsdPharmacologysd(Q19–Q30)
● ModulesdD:sdEndocrinesd&sdMetabolicsdTherapeuticssd(Q31–Q40)
● ModulesdE:sdRespiratory,sdAnti-Infective,sd&sdImmunesdModulationsd(Q41–Q48)
● ModulesdF:sdSpecialsdPopulations:sdGeriatrics,sdPediatrics,sd&sdDeprescribingsd(Q
49–Q55)
THEsd"HIGH-YIELDsdTOOLKIT"
MechanisticsdClarifier:sdDeconstru
ctingsdthesd"FatalsdPairs"
Insdthesdcontextsdofsdthesd2026sdexamsdcycle,sdrotesdmemorizationsdofsddrugsdclassessd
issdinsufficient.sdThesdNextsdGenerationsdNCLEXsd(NGN)sdandsdupdatedsdCPNREsdbluep
rintssdtestsdthesdcandidate'ssdabilitysdtosddistinguishsdbetweensdphysiologicallysdsimilarsdb
utsdclinicallysddistinctsdstates.sdThesdfollowingsdcomparisonsdtablesddissectssdthesdmostsdf
requentlysdconfusedsdconceptssdthatsdleadsdtosdcriticalsdsafetysderrors,sdintegratingsdspeci
ficsdCanadiansdnuancessdfromsdthesd2025–2026sdpracticesdstandards.
ConceptsdPair MechanisticsdDiverge ClinicalsdDifferentiat 2026sdCanadian
nce orsd(Thesd"Tell") sdPracticesdCo
ntext
,CholinergicsdCrisissd Cholinergic:sdExces Secretionssd&sdTimi TrapsdAlert:sdWhiles
vs. sivesdaccumulationsd ng:sdCholinergicsdCri dthesdTensilonsdtests
MyasthenicsdCrisis ofsdacetylcholinesd(A sis:sd"Wet"sdsympto dissdasdclassicsdexa
Ch)sdatsdthesdneuro mssd(Salivation,sdLac msdtopic,sd2026sdprot
muscularsdjunctionsd rimation,sdUrination,s ocolssdemphasizesdre
duesdtosdoverdosesd dDefecationsd- spiratorysdfailuresd
ofsdanticholinesterase sdSLUDge).sdOccurss managementsdfirst.sdI
sdtherapy.sdResultss d30-60sdminssdpost- ntubationsdtakessdpre
dinsdcontinuoussddep medication. cedencesdoversddiagn
olarizationsdandsdrec MyasthenicsdCrisis:sd osticsdtestingsdinsdac
eptorsddesensitization "Dry"sdweakness.sdR utesddistress.sdThesd
. espiratorysdfailuresdwi FDAsdandsdHealthsd
Myasthenic: thoutsdthesdexcessive Canadasdhavesdmove
sdsecretions.sdOccurs dsdawaysdfromsdEdro
sddue phoniumsdduesdto
tosdmissedsddosessdo
r
ConceptsdPair Mechanistic ClinicalsdDifferentiato 2026sdCanadian
Divergence r PracticesdContext
(Thesd"Tell")
InsufficientsdAChsdats infection.sdEdrophoni cardiacsdarrestsdrisk;sd
dthesdjunctionsdduesd umsd(Tensilon)sdTes looksdforsd"IcesdPack
tosddiseasesdexacerb tsdResponse:sdCholi sdTest"sdassdthesdmo
ationsd(autoimmunesd nergicsdCrisis:sdSymp dernsdbedsidesdaltern
destructionsdofsdrece tomssdWORSEN.sdMy ative.
ptors)sdor asthenicsdCrisis:sdSy
under-dosing. mptomssdIMPROVE.
SerotoninsdSyndro SS: NeuromuscularsdTon Withsdthesdrisesdofsd
mesd(SS)sdvs.sdNe Hypersensitivity/Oversti e:sdSS:sdHyperreflex polypharmacysdinsdC
urolepticsdMalignan sdmulationsdofsd5- ia,sdclonussd(rhythmic anadiansdmentalsdhealt
tsdSyndromesd(NM HT2Asdreceptorssdins sdjerking),sdandsdmy hsd(e.g.,sdcombiningsd
S) dthesdbrainstemsdand driasissd(dilatedsdpupi SSRIssdwithsdnewersd
sdspinalsdcord.sdOnse ls).sdNMS:sd"Lead- antipsychoticssdlikesdL
tsdissdRAPIDsd(hours pipe"sdrigidity,sdhyp urasidone),sddistinguis
).sdNMS:sdDopamines oreflexia,sdandsdnorm hingsdthesesdemergen
dD2sdreceptorsdblocka alsdpupils. tsdstatessdissdasdcritic
desdinsdthesdnigrostri Mnemonic:sd"SSsd=s alsdsafetysdcompetenc
atalsdpathwaysdandsd dShakingsd&sdsweaty y.sdThesdtreatmentsdf
hypothalamus. sd(fast);sdNMSsd=sd orsdSSsdissdCyprohep
OnsetsdissdGRADUAL Nosdmotionsd&sdslow tadine;sdforsdNMS,sdit
(dayssdtosdweeks). ." sdissdDantrolene.
, ACEsdInhibitorssd(- ACEsdInhibitors:sdBl ThesdCoughsd&sdAn RenalsdProtection:s
prils) ocksdthesdconversions gioedema:sdAccumula dBothsdaresdfirst-
vs.sdARBssd(- dofsdAngiotensinsdIsdt tionsdofsdBradykininsdi linesdforsddiabeticsd
sartans) osdIIsdandsdinhibitsdth nsdthesdlungssdcause nephropathysdinsdC
esdbreakdownsdofsdBr ssdthesddrysdcoughsd anada.sdThesd2026s
adykinin.sdARBs:sdBl andsdhighersdrisksdofs dguidelinessdemphasi
ocksdAngiotensinsdIIsd dangioedemasdinsdAC zesdswitchingsdtosdA
receptorssddirectly.sdD Esdinhibitors.sdARBssd RBssdimmediatelysdif
osdNOTsdaffectsdBrad aresdthesdalternativesd sdcoughsdimpactssda
ykininsdbreakdown. whensdthesesdsidesde dherence,sdassdadher
ffectssdoccur. encesdissdasdkeysdm
etricsdinsdchronic
diseasesdmanagement.
Heparinsd(Unfracti Heparin:sdActivatess MonitoringsdLabs:sd High-
onated)sdvs.sdWarf dAntithrombinsdIII,sdw Heparin:sdaPTTsd(Targ AlertsdStatus:sdISM
arin hichsdinactivatessdTh et:sd1.5– PsdCanadasd(2025)s
rombinsdandsdFactor 2.5xsdcontrol). dlistssdbothsdassdhigh
sdXa.sdWorkssdIMME Antidote:sdProtamines -
DIATELYsdinsdthesd dSulfate.sdWarfarin:sdI alert.sdUnderstanding
blood.sdWarfarin:sdI NRsd(Target:sd2.0– sdthesd"Bridge"sdissd
nhibitssdVitamin 3.0). vitalsdforsdtransitions
K- Antidote:sdVitaminsdK dofsdcaresd(hospitals
dependentsdsynthesis sd/sdPCC.sdBridgesdT dtosdcommunity).sdEr
sdofsdFactorssdII,sdVI herapy:sdBothsdaresd rorssdheresdaresdasd
I,sdIX,sdXsdinsdthesdl usedsdsimultaneously leadingsdcausesdofsd
iver.sdTakessdDAYSs sduntilsdINRsdissdthe readmission.sdBesda
dtosdworksd(Effect rapeutic. waresdofsdHITsd(Hep
dependssdonsddepletin arinsdInduced
g
ConceptsdPair Mechanistic ClinicalsdDifferentiato 2026sdCanadian
Divergence r PracticesdContext
(Thesd"Tell")
existingsdfactors). Thrombocytopenia)sdw
hichsdprohibitssdfutures
dHeparin/LMWHsduse.
Typesd1sd(DKA)sdvs.s DKA:sdAbsolutesdinsu Acidosissdvs.sdOsm 2026sdDiabetessdCan
dTypesd2sd(HHS)sdC linsddeficiencysdleadin olarity:sdDKA:sdKuss adasdUpdate:sdFluids
risis gsdtosdketosis.sdpHsd maulsdrespirationssd(b dresuscitationsdissdthe
<sd7.35,sdKetonessdin lowingsdoffsdCO2),sdfr sdprioritysdinsdboth.
sdurine/blood.sdRapids uitysdbreath,sdmetabol However,sdinsdDKA,s
donset.sdHHS:sdRelati icsdacidosis.sdHHS:sd dpotassiumsdreplacem
vesdinsulinsddeficiency Profoundsddehydration entsdmustsdoccursdbe
sdpreventssdketosissd ,sdconfusion/coma,sdN foresdinsulinsdifsdK+s
butsdallowssdseveresd Osdketones/acidosis. d<sd3.3sdmmol/Lsdtos
hyperglycemiasd(>34s dpreventsdcardiacsdar
dmmol/L)sdandsddehy rest.sdThissdsequenci
dration.sdGradual ngsdissda
onset. high-
